Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Ban Reaction Cautious From Most In Industry; Overdue, Hatch Says

This article was originally published in The Tan Sheet

Executive Summary

The dietary supplement industry is taking a wait-and-see attitude about FDA's imminent rule banning ephedrine alkaloid-containing dietary supplements
Advertisement

Related Content

Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
NNFA Praises DSHEA Implementation Act, Promotes It As S 722 Alternative

Topics

Advertisement
UsernamePublicRestriction

Register

PS096315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel